|
1
|
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.
|
J Am Soc Echocardiogr
|
2005
|
46.32
|
|
2
|
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
|
N Engl J Med
|
2009
|
14.13
|
|
3
|
Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.
|
J Am Soc Echocardiogr
|
2010
|
13.12
|
|
4
|
Cardiac-resynchronization therapy for the prevention of heart-failure events.
|
N Engl J Med
|
2009
|
12.44
|
|
5
|
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
|
N Engl J Med
|
2014
|
11.77
|
|
6
|
Strategies for multivessel revascularization in patients with diabetes.
|
N Engl J Med
|
2012
|
10.79
|
|
7
|
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
N Engl J Med
|
2003
|
10.57
|
|
8
|
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
|
N Engl J Med
|
2012
|
9.46
|
|
9
|
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
|
N Engl J Med
|
2004
|
9.13
|
|
10
|
Celecoxib for the prevention of sporadic colorectal adenomas.
|
N Engl J Med
|
2006
|
7.62
|
|
11
|
Spironolactone for heart failure with preserved ejection fraction.
|
N Engl J Med
|
2014
|
7.48
|
|
12
|
Celecoxib for the prevention of colorectal adenomatous polyps.
|
N Engl J Med
|
2006
|
6.15
|
|
13
|
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
|
JAMA
|
2012
|
5.27
|
|
14
|
Treatment of anemia with darbepoetin alfa in systolic heart failure.
|
N Engl J Med
|
2013
|
4.67
|
|
15
|
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
|
N Engl J Med
|
2015
|
4.56
|
|
16
|
Survival with cardiac-resynchronization therapy in mild heart failure.
|
N Engl J Med
|
2014
|
3.80
|
|
17
|
The amyloidogenic V122I transthyretin variant in elderly black Americans.
|
N Engl J Med
|
2015
|
3.36
|
|
18
|
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy.
|
Circulation
|
2002
|
3.20
|
|
19
|
Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study.
|
Am J Respir Crit Care Med
|
2013
|
3.09
|
|
20
|
Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation.
|
Mol Ther
|
2006
|
2.85
|
|
21
|
Albuminuria in chronic heart failure: prevalence and prognostic importance.
|
Lancet
|
2009
|
2.79
|
|
22
|
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
|
Circulation
|
2004
|
2.73
|
|
23
|
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.
|
Circulation
|
2002
|
2.65
|
|
24
|
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
|
Eur Heart J
|
2008
|
2.47
|
|
25
|
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.
|
Am Heart J
|
2012
|
2.42
|
|
26
|
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
|
Circulation
|
2007
|
2.41
|
|
27
|
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.
|
J Am Coll Cardiol
|
2012
|
2.31
|
|
28
|
Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction.
|
J Am Coll Cardiol
|
2010
|
2.29
|
|
29
|
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
|
JACC Cardiovasc Imaging
|
2008
|
2.24
|
|
30
|
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
|
Hypertension
|
2007
|
2.22
|
|
31
|
Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism.
|
Circulation
|
2004
|
2.21
|
|
32
|
Echocardiographic and lung ultrasound characteristics in ambulatory patients with dyspnea or prior heart failure.
|
Echocardiography
|
2013
|
2.11
|
|
33
|
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
|
Am J Kidney Dis
|
2011
|
2.05
|
|
34
|
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
|
Nephrol Dial Transplant
|
2009
|
2.02
|
|
35
|
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
|
Circulation
|
2010
|
2.00
|
|
36
|
Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy).
|
J Am Coll Cardiol
|
2011
|
1.95
|
|
37
|
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
|
Am Heart J
|
2011
|
1.95
|
|
38
|
Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury.
|
J Immunol
|
2005
|
1.89
|
|
39
|
Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction.
|
J Am Coll Cardiol
|
2002
|
1.87
|
|
40
|
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
|
Circulation
|
2011
|
1.87
|
|
41
|
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
|
J Am Coll Cardiol
|
2012
|
1.87
|
|
42
|
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
|
Eur Heart J
|
2008
|
1.84
|
|
43
|
Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
|
J Am Coll Cardiol
|
2013
|
1.83
|
|
44
|
The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
|
J Am Coll Cardiol
|
2013
|
1.79
|
|
45
|
Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial.
|
Eur J Heart Fail
|
2012
|
1.76
|
|
46
|
Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation.
|
Am Heart J
|
2011
|
1.71
|
|
47
|
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
|
J Renin Angiotensin Aldosterone Syst
|
2012
|
1.68
|
|
48
|
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.
|
J Am Coll Cardiol
|
2013
|
1.65
|
|
49
|
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
|
Circ Heart Fail
|
2008
|
1.65
|
|
50
|
Utility of lung ultrasound in predicting pulmonary and cardiac pressures.
|
Eur J Heart Fail
|
2012
|
1.63
|
|
51
|
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
|
Circ Heart Fail
|
2012
|
1.62
|
|
52
|
Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial--Cardiac Resynchronization Therapy (MADIT-CRT).
|
Heart Rhythm
|
2010
|
1.60
|
|
53
|
A clinician's guide to tissue Doppler imaging.
|
Circulation
|
2006
|
1.59
|
|
54
|
Dyssynchrony and the risk of ventricular arrhythmias.
|
JACC Cardiovasc Imaging
|
2013
|
1.56
|
|
55
|
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction.
|
Eur J Heart Fail
|
2010
|
1.55
|
|
56
|
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
|
J Am Coll Cardiol
|
2012
|
1.55
|
|
57
|
Calibrating parametric subject-specific risk estimation.
|
Biometrika
|
2010
|
1.54
|
|
58
|
Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRT.
|
Heart Rhythm
|
2013
|
1.52
|
|
59
|
Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study.
|
Echocardiography
|
2007
|
1.51
|
|
60
|
Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities).
|
JACC Heart Fail
|
2013
|
1.51
|
|
61
|
Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation.
|
J Am Soc Echocardiogr
|
2009
|
1.49
|
|
62
|
Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study).
|
Am J Cardiol
|
2008
|
1.49
|
|
63
|
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
|
Eur J Heart Fail
|
2015
|
1.49
|
|
64
|
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT).
|
Eur Heart J
|
2009
|
1.48
|
|
65
|
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.
|
Eur Heart J
|
2013
|
1.47
|
|
66
|
Classification of acute decompensated heart failure: an automated algorithm compared with a physician reviewer panel: the Atherosclerosis Risk in Communities study.
|
Circ Heart Fail
|
2013
|
1.47
|
|
67
|
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
|
J Am Coll Cardiol
|
2008
|
1.45
|
|
68
|
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
|
J Am Coll Cardiol
|
2013
|
1.44
|
|
69
|
Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension.
|
Eur J Heart Fail
|
2014
|
1.44
|
|
70
|
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
|
Heart Rhythm
|
2006
|
1.41
|
|
71
|
Dietary sodium intake modulates myocardial relaxation responsiveness to angiotensin II.
|
Transl Res
|
2006
|
1.40
|
|
72
|
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
|
Circ Heart Fail
|
2013
|
1.40
|
|
73
|
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
|
J Am Coll Cardiol
|
2007
|
1.38
|
|
74
|
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
|
Eur J Heart Fail
|
2010
|
1.38
|
|
75
|
Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study.
|
Circ Cardiovasc Imaging
|
2013
|
1.37
|
|
76
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
77
|
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Circulation
|
2004
|
1.33
|
|
78
|
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.
|
Hypertension
|
2007
|
1.29
|
|
79
|
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
|
Eur J Heart Fail
|
2013
|
1.29
|
|
80
|
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
|
Circulation
|
2006
|
1.28
|
|
81
|
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.
|
J Am Soc Nephrol
|
2006
|
1.26
|
|
82
|
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
|
Am Heart J
|
2005
|
1.25
|
|
83
|
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
|
Circulation
|
2010
|
1.24
|
|
84
|
Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
|
Clin Trials
|
2012
|
1.22
|
|
85
|
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
|
Eur J Heart Fail
|
2006
|
1.22
|
|
86
|
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
|
JAMA
|
2013
|
1.21
|
|
87
|
Myocardial deformation imaging: current status and future directions.
|
Circulation
|
2012
|
1.19
|
|
88
|
Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren.
|
Eur J Heart Fail
|
2011
|
1.18
|
|
89
|
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
|
Circulation
|
2007
|
1.17
|
|
90
|
Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study.
|
Eur Heart J
|
2008
|
1.16
|
|
91
|
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).
|
Am Heart J
|
2011
|
1.15
|
|
92
|
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
|
Eur Heart J
|
2008
|
1.15
|
|
93
|
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
|
Circulation
|
2004
|
1.15
|
|
94
|
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
Eur J Heart Fail
|
2009
|
1.13
|
|
95
|
The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study.
|
J Am Coll Cardiol
|
2007
|
1.13
|
|
96
|
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function.
|
Eur Heart J
|
2007
|
1.11
|
|
97
|
Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction.
|
Eur Heart J
|
2012
|
1.11
|
|
98
|
The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%).
|
Eur J Heart Fail
|
2014
|
1.10
|
|
99
|
Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury.
|
Proc Natl Acad Sci U S A
|
2004
|
1.09
|
|
100
|
Dyssynchrony, contractile function, and response to cardiac resynchronization therapy.
|
Circ Heart Fail
|
2011
|
1.05
|
|
101
|
Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction.
|
Congest Heart Fail
|
2007
|
1.04
|
|
102
|
Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.
|
Circ Heart Fail
|
2009
|
1.04
|
|
103
|
Mortality rates in trials of subjects with type 2 diabetes.
|
J Am Heart Assoc
|
2012
|
1.04
|
|
104
|
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
|
Eur Heart J
|
2009
|
1.03
|
|
105
|
Reproducibility of speckle-tracking-based strain measures of left ventricular function in a community-based study.
|
J Am Soc Echocardiogr
|
2013
|
1.03
|
|
106
|
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
|
Eur Heart J
|
2009
|
1.03
|
|
107
|
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial.
|
Eur J Heart Fail
|
2009
|
1.03
|
|
108
|
Right ventricular dysfunction and adverse outcome in patients with advanced heart failure.
|
J Card Fail
|
2006
|
1.02
|
|
109
|
Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging.
|
J Cardiovasc Magn Reson
|
2006
|
1.01
|
|
110
|
Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.
|
Circulation
|
2011
|
1.01
|
|
111
|
Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
|
Circulation
|
2014
|
1.00
|
|
112
|
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.
|
Eur J Heart Fail
|
2010
|
1.00
|
|
113
|
Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial).
|
Am J Cardiol
|
2004
|
0.99
|
|
114
|
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
|
Am Heart J
|
2010
|
0.99
|
|
115
|
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction.
|
J Am Heart Assoc
|
2013
|
0.98
|
|
116
|
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
|
Eur J Heart Fail
|
2014
|
0.98
|
|
117
|
Effect of peri-infarct pacing early after myocardial infarction: results of the prevention of myocardial enlargement and dilatation post myocardial infarction study.
|
Circ Heart Fail
|
2010
|
0.98
|
|
118
|
Age- and sex-based reference limits and clinical correlates of myocardial strain and synchrony: the Framingham Heart Study.
|
Circ Cardiovasc Imaging
|
2013
|
0.97
|
|
119
|
Impaired left atrial function in heart failure with preserved ejection fraction.
|
Eur J Heart Fail
|
2014
|
0.96
|
|
120
|
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved.
|
Eur J Heart Fail
|
2013
|
0.96
|
|
121
|
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
|
J Am Soc Echocardiogr
|
2006
|
0.96
|
|
122
|
Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study.
|
JACC Heart Fail
|
2013
|
0.95
|
|
123
|
Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
0.95
|
|
124
|
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
|
Am J Kidney Dis
|
2009
|
0.95
|
|
125
|
Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy.
|
J Cardiovasc Electrophysiol
|
2011
|
0.94
|
|
126
|
Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).
|
J Am Coll Cardiol
|
2011
|
0.92
|
|
127
|
Diastolic dysfunction as a link between hypertension and heart failure.
|
Med Clin North Am
|
2009
|
0.92
|
|
128
|
Angiotensin II receptor blockade and ventricular remodelling.
|
J Renin Angiotensin Aldosterone Syst
|
2005
|
0.92
|
|
129
|
Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial.
|
Eur Heart J
|
2011
|
0.92
|
|
130
|
Left ventricular assessment in myocardial infarction: the VALIANT registry.
|
Arch Intern Med
|
2005
|
0.92
|
|
131
|
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
|
Eur Heart J
|
2008
|
0.91
|
|
132
|
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
|
Eur J Heart Fail
|
2014
|
0.90
|
|
133
|
Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery.
|
J Am Coll Cardiol
|
2006
|
0.90
|
|
134
|
Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials.
|
J Card Fail
|
2002
|
0.90
|
|
135
|
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.
|
Clin J Am Soc Nephrol
|
2011
|
0.90
|
|
136
|
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial.
|
Heart Rhythm
|
2006
|
0.90
|
|
137
|
Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial.
|
Eur Heart J
|
2006
|
0.89
|
|
138
|
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension.
|
J Hypertens
|
2011
|
0.89
|
|
139
|
Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction.
|
Am J Cardiol
|
2010
|
0.89
|
|
140
|
Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.
|
Clin Chem
|
2011
|
0.89
|
|
141
|
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.
|
Eur Heart J
|
2013
|
0.89
|
|
142
|
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.
|
Ann Intern Med
|
2015
|
0.89
|
|
143
|
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
|
Am J Cardiol
|
2008
|
0.87
|
|
144
|
Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction.
|
Eur J Heart Fail
|
2014
|
0.87
|
|
145
|
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease.
|
Am J Nephrol
|
2011
|
0.87
|
|
146
|
Point-of-care echocardiography in the accountable care organization era.
|
Circ Cardiovasc Imaging
|
2012
|
0.86
|
|
147
|
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
|
Eur J Heart Fail
|
2008
|
0.86
|
|
148
|
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
|
Eur Heart J
|
2008
|
0.85
|
|
149
|
Value of the electrocardiogram in predicting left ventricular enlargement and dysfunction after myocardial infarction.
|
Am J Med
|
2003
|
0.85
|
|
150
|
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both.
|
Am Heart J
|
2011
|
0.84
|
|
151
|
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
|
Eur J Heart Fail
|
2013
|
0.84
|
|
152
|
Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.
|
Eur J Heart Fail
|
2011
|
0.84
|
|
153
|
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
|
Eur J Heart Fail
|
2010
|
0.84
|
|
154
|
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2005
|
0.84
|
|
155
|
Therapeutic approaches to diastolic dysfunction.
|
Curr Hypertens Rep
|
2009
|
0.84
|
|
156
|
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
|
Am Heart J
|
2007
|
0.84
|
|
157
|
Race influences the safety and efficacy of spironolactone in severe heart failure.
|
Circ Heart Fail
|
2013
|
0.84
|
|
158
|
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Am Heart J
|
2008
|
0.83
|
|
159
|
ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme.
|
Drugs
|
2006
|
0.83
|
|
160
|
Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power.
|
J Clin Epidemiol
|
2010
|
0.83
|
|
161
|
Are we asking too much of our trials?
|
Am Heart J
|
2002
|
0.83
|
|
162
|
Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure.
|
JACC Cardiovasc Imaging
|
2012
|
0.83
|
|
163
|
Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure.
|
Circ Heart Fail
|
2013
|
0.82
|
|
164
|
Regional right ventricular strain pattern in patients with acute pulmonary embolism.
|
Echocardiography
|
2012
|
0.82
|
|
165
|
Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
|
Curr Opin Cardiol
|
2006
|
0.82
|
|
166
|
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
|
Eur J Heart Fail
|
2011
|
0.82
|
|
167
|
Changes in central arterial pressure waveforms during the normal menstrual cycle.
|
J Investig Med
|
2006
|
0.81
|
|
168
|
Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease.
|
Am J Hypertens
|
2013
|
0.81
|
|
169
|
Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency.
|
Eur Heart J
|
2012
|
0.81
|
|
170
|
Images in cardiovascular medicine. Initial presentation of an accessory left ventricle in a patient with syncope.
|
Circulation
|
2010
|
0.81
|
|
171
|
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
|
Am J Cardiol
|
2008
|
0.81
|
|
172
|
Left ventricular mechanical function: clinical correlates, heritability, and association with parental heart failure.
|
Eur J Heart Fail
|
2014
|
0.81
|
|
173
|
Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity.
|
Eur Heart J
|
2010
|
0.80
|
|
174
|
Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
|
Cardiol Clin
|
2008
|
0.80
|
|
175
|
Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study.
|
Hypertension
|
2013
|
0.80
|
|
176
|
Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D.
|
Heart Rhythm
|
2013
|
0.80
|
|
177
|
Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.
|
Cardiovasc Drugs Ther
|
2011
|
0.80
|
|
178
|
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction.
|
J Am Soc Echocardiogr
|
2012
|
0.80
|
|
179
|
Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease.
|
Am J Cardiol
|
2011
|
0.80
|
|
180
|
Renin-angiotensin system and cardiac rupture after myocardial infarction.
|
Circulation
|
2002
|
0.79
|
|
181
|
A unified view of ventricular remodelling.
|
Eur J Heart Fail
|
2010
|
0.79
|
|
182
|
Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism.
|
Am J Cardiol
|
2005
|
0.79
|
|
183
|
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients.
|
Eur J Heart Fail
|
2013
|
0.79
|
|
184
|
Neprilysin inhibition for heart failure.
|
N Engl J Med
|
2014
|
0.79
|
|
185
|
Response of right ventricular size to treatment with cardiac resynchronization therapy and the risk of ventricular tachyarrhythmias in MADIT-CRT.
|
Heart Rhythm
|
2013
|
0.79
|
|
186
|
B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients.
|
Transplantation
|
2016
|
0.78
|
|
187
|
Aldosterone antagonism and myocardial infarction: from animals to man and back.
|
J Am Coll Cardiol
|
2003
|
0.78
|
|
188
|
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT.
|
Int J Cardiol
|
2012
|
0.78
|
|
189
|
Right ventricular function, pulmonary pressure estimation, and clinical outcomes in cardiac resynchronization therapy.
|
Circ Heart Fail
|
2013
|
0.78
|
|
190
|
Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction.
|
Am J Cardiol
|
2003
|
0.78
|
|
191
|
Site selection for heart failure clinical trials in the USA.
|
Heart Fail Rev
|
2015
|
0.78
|
|
192
|
Echocardiographic evaluation of coronary artery disease.
|
Coron Artery Dis
|
2013
|
0.78
|
|
193
|
Left ventricular diastolic function following myocardial infarction.
|
Curr Heart Fail Rep
|
2006
|
0.77
|
|
194
|
Treatment of asymptomatic left ventricular dysfunction.
|
Curr Treat Options Cardiovasc Med
|
2008
|
0.77
|
|
195
|
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.
|
Am Heart J
|
2006
|
0.77
|
|
196
|
Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience.
|
J Am Soc Echocardiogr
|
2006
|
0.77
|
|
197
|
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
Am Heart J
|
2006
|
0.77
|
|
198
|
Variable impact of combining fatal and nonfatal end points in heart failure trials.
|
Circulation
|
2006
|
0.77
|
|
199
|
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
|
J Renin Angiotensin Aldosterone Syst
|
2011
|
0.77
|
|
200
|
Effects of cardiac resynchronization therapy on left ventricular mass and wall thickness in mild heart failure patients in MADIT-CRT.
|
Heart Rhythm
|
2012
|
0.77
|
|
201
|
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.
|
J Renin Angiotensin Aldosterone Syst
|
2012
|
0.77
|
|
202
|
Vitamin D Therapy and Cardiac Function in Chronic Kidney Disease-Reply.
|
JAMA
|
2012
|
0.76
|
|
203
|
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
|
Eur J Heart Fail
|
2015
|
0.76
|
|
204
|
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
|
Eur J Heart Fail
|
2015
|
0.76
|
|
205
|
Long-term outcome with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block from US and Europe MADIT-CRT.
|
Heart Fail Rev
|
2015
|
0.76
|
|
206
|
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
|
Curr Heart Fail Rep
|
2007
|
0.75
|
|
207
|
Reply from the authors.
|
Am J Respir Crit Care Med
|
2014
|
0.75
|
|
208
|
Dual renin-angiotensin system blockade and kidney disease.
|
J Am Coll Cardiol
|
2009
|
0.75
|
|
209
|
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
|
N Engl J Med
|
2015
|
0.75
|
|
210
|
Reply: To PMID 24028294.
|
Echocardiography
|
2014
|
0.75
|
|
211
|
Reducing infarct size with EPO in patients with ST-segment elevation myocardial infarction.
|
Am J Kidney Dis
|
2011
|
0.75
|
|
212
|
V122I transthyretin variant in elderly black Americans.
|
N Engl J Med
|
2015
|
0.75
|
|
213
|
Mitral regurgitation in transcatheter aortic valve replacement: the complexity of multivalvular disease.
|
Circulation
|
2013
|
0.75
|
|
214
|
Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT.
|
Eur J Heart Fail
|
2014
|
0.75
|
|
215
|
Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function.
|
J Hypertens
|
2014
|
0.75
|
|
216
|
Mapping directions for the cardiorenal conundrum: where you end up depends upon where you started, so where do we go from here?
|
J Am Coll Cardiol
|
2008
|
0.75
|
|
217
|
Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?
|
J Am Coll Cardiol
|
2014
|
0.75
|
|
218
|
Vasodilators across the heart failure spectrum not all patients, and not all vasodilators, are created equal.
|
J Am Coll Cardiol
|
2012
|
0.75
|
|
219
|
Long-term prognostic importance of diabetes after a myocardial infarction depends on left ventricular systolic function.
|
Diabetes Care
|
2011
|
0.75
|
|
220
|
Reply to "The role of fibroblast growth factor-23 in left atrial volume".
|
Am Heart J
|
2013
|
0.75
|
|
221
|
Influence of Physical Activity on Hypertension and Cardiac Structure and Function.
|
Curr Hypertens Rep
|
2015
|
0.75
|
|
222
|
Acute effects of withdrawal of cardiac resynchronization therapy on left and right ventricular function, dyssynchrony, and contractile function in patients with New York Heart Association functional class I/II heart failure: MADIT-CRT.
|
J Card Fail
|
2013
|
0.75
|
|
223
|
Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention.
|
Circulation
|
2011
|
0.75
|
|
224
|
Does influenza vaccination influence cardiovascular complications?
|
Expert Rev Cardiovasc Ther
|
2015
|
0.75
|
|
225
|
The Authors Reply.
|
JACC Cardiovasc Imaging
|
2016
|
0.75
|
|
226
|
Uncertainty in the treatment of anemia in chronic kidney disease.
|
Rev Cardiovasc Med
|
2005
|
0.75
|
|
227
|
P-wave morphology is associated with echocardiographic response to cardiac resynchronization therapy in MADIT-CRT patients.
|
Ann Noninvasive Electrocardiol
|
2013
|
0.75
|
|
228
|
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction.
|
Am Heart J
|
2011
|
0.75
|
|
229
|
Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials.
|
Curr Heart Fail Rep
|
2008
|
0.75
|
|
230
|
Reply: The Benefit of Cardiac Resynchronization Therapy Is Not Hindered by the Number of Comorbidities.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
231
|
Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease.
|
J Hypertens
|
2014
|
0.75
|
|
232
|
Diagnostic evaluation: target organ damage: cardiac.
|
J Am Soc Hypertens
|
2014
|
0.75
|
|
233
|
Remodeling and recovery following myocardial infarction.
|
Ital Heart J
|
2003
|
0.75
|
|
234
|
Prognostic use of echocardiography 1 year after a myocardial infarction.
|
Am Heart J
|
2005
|
0.75
|